For years, much of cancer research has focused on understanding the tumor itself — how cancer cells grow, what causes them to change and how those cells can be targeted with treatment. But researchers ...

Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation ...

Independent radiology review showed 94% ORR (15% CR) in 94 TKI-naïve ROS1+ NSCLC patients receiving 100 mg daily, with median DoR and PFS not reached. Central nervous system efficacy was robust: 10/10 ...

Cancer care complexity arises from multiple disease subtypes, expanding therapeutic sequences, and individualized constraints from comorbidities, concurrent medications, and drug–drug interactions.

I have been living with stage IV kidney cancer for more than ten years. By now, I have had more CT scans, MRIs, PET scans, blood tests and follow-up appointments than I could ever count. You would ...

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant ...

A dedicated movement space can serve as a survivorship anchor, reinforcing identity, agency, and continuity through training ...

A peritoneal mesothelioma diagnosis at 21, five months postpartum, underscores the psychosocial burden of rare malignancy in ...

In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology ...